Compile Data Set for Download or QSAR
maximum 50k data
Found 388 Enz. Inhib. hit(s) with all data for entry = 1416
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321855(US10183021, Compound I-595)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321856(US10183021, Compound I-587)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321857(US10183021, Compound I-596)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321858(US10183021, Compound I-588)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321859(US10183021, Compound I-597)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321860(US10183021, Compound I-589)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321861(US10183021, Compound I-598)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321862(US10183021, Compound I-590)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321863(US10183021, Compound I-599)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321656(US10183021, Compound I-401)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321657(US10183021, Compound I-318)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321658(US10183021, Compound I-416)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321659(US10183021, Compound I-319)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321660(US10183021, Compound I-412)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321661(US10183021, Compound I-320)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321662(US10183021, Compound I-357)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321663(US10183021, Compound I-394)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321664(US10183021, Compound I-164)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321665(US10183021, Compound I-430)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321666(US10183021, Compound I-405)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321667(US10183021, Compound I-431)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321668(US10183021, Compound I-327)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321669(US10183021, Compound I-349)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321670(US10183021, Compound I-328)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321671(US10183021, Compound I-415)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321672(US10183021, Compound I-499)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321673(US10183021, Compound I-362)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321674(US10183021, Compound I-500)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321675(US10183021, Compound I-386)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321676(US10183021, Compound I-501)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321677(US10183021, Compound I-402)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321678(US10183021, Compound I-502)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321679(US10183021, Compound I-456)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321680(US10183021, Compound I-503)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321681(US10183021, Compound I-457)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321682(US10183021, Compound I-504)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321683(US10183021, Compound I-458)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321684(US10183021, Compound I-505)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321685(US10183021, Compound I-459)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321686(US10183021, Compound I-506)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321687(US10183021, Compound I-460)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321688(US10183021, Compound I-507)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321689(US10183021, Compound I-461)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321690(US10183021, Compound I-418)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321691(US10183021, Compound I-462)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321692(US10183021, Compound I-508)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321693(US10183021, Compound I-463)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321694(US10183021, Compound I-509)
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321695(US10183021, Compound I-464)
Affinity DataEC50:  550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals

US Patent
LigandPNGBDBM321696(US10183021, Compound I-446)
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 388 total ) | Next | Last >>
Jump to: